What is claimed is:

1. Use of a) a human anti-PD-L1 antibody or an antigen binding fragment thereof, b) etoposide and a platinum-based therapeutic agent (EP) in the manufacture of a medicament for~~A method of~~ extending progression-free survival (PFS) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the human anti-PD-L1 antibody or antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

wherein PFS is increased by at least about five months versus treatment with EP alone~~comprising treating the patient with~~

~~a) a human anti-PD-L1 antibody and~~

~~b) etoposide and a platinum-based therapeutic agent (EP),~~

~~wherein the human anti-PD-L1 antibody is administered as a fixed dose of 1500 mg, intravenously, every three weeks (Q3W) or~~

~~wherein the human anti-PD-L1 antibody is administered as a dose of 20 mg/kg, intravenously, Q3W~~.

2. The ~~method~~ use of claim 1, wherein the platinum-based therapeutic agent comprises cisplatin and/or carboplatin.

3. The ~~method~~ use of claim 1, wherein the human anti-PD-L1 antibody or antigen binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

~~4. The method of claim 1, wherein the human anti-PD-L1 antibody comprises:~~

~~a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.~~

4~~5~~. The ~~method~~ use of claim 1, wherein the human anti-PD-L1 antibody is durvalumab~~,~~ ~~avelumab, or atezolizumab~~.

5. The use of claim 1, wherein the human anti-PD-L1 antibody is to be administered as a fixed dose of 1500 mg, intravenously, every three weeks (Q3W) or as a dose of 20 mg/kg, intravenously, Q3W.

6. The ~~method~~ use of claim 5~~1~~, wherein the ~~method~~ use comprises 4 cycles of administration of the human anti-PD-L1 antibody.

7. The ~~method~~ use of claim 5~~1~~ or 6, wherein EP is to be administered as a dose comprising 80-100 mg/m$^2$ etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m$^2$, intravenously, per dose of human anti-PD-L1 antibody.

8. The use of any one of claims 5-7, wherein ~~method of any one of claims 1, 6, or 7 further comprising administration of~~ 1500 mg human anti-PD-L1 antibody is to be administered, intravenously, Q4W after completion of 4 cycles of Q3W.

9. The use of any one of claims 5-7, wherein a human anti-CTLA-4 antibody is to be administered, intravenously, Q3W, wherein the human anti-CTLA-4 antibody is tremelimumab~~method of any one of claims 1, 6, or 7 further comprising administration of a human anti-CTLA-4 antibody, intravenously, Q3W~~.

~~10. The method of claim 9, wherein the human anti-CTLA-4 antibody is tremelimumab.~~

1~~1~~0. The use of claim 9, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kg~~method of claim 10, wherein tremelimumab is administered as a fixed dose of 75 mg~~.

~~12. The method of claim 10, wherein tremelimumab is administered as a dose of 1 mg/kg.~~

~~13~~11. The use according to any of the preceding claims, wherein prophylactic cranial irradiation is to be administered~~method according to any of the preceding claims further comprising administration of prophylactic cranial irradiation~~ to the patient.

~~14. The method according to any of the preceding claims further comprising treating the patient with a human anti-PD-1 antibody.~~

1~~5~~2. The use according to any of the preceding claims, wherein the medicament includes a human anti-PD-1 antibody, wherein ~~method of claim 14, wherein~~ the human anti-PD-1 antibody comprises pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®).

~~16. The method of claim 1, wherein PFS is increased by at least about five months versus treatment with EP alone.~~

~~17~~13. Use of a) a human anti-PD-L1 antibody or an antigen binding fragment thereof, b) etoposide and a platinum-based therapeutic agent (EP) in the manufacture of a medicament for ~~A method of~~ extending overall survival (OS) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the human anti-PD-L1 antibody or antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

wherein OS is extended by at least about three months versus treatment with EP alone~~comprising treating the patient with~~

~~a) a human anti-PD-L1 antibody; and~~

~~b) etoposide and a platinum-based therapeutic agent (EP),~~

~~wherein the human anti-PD-L1 antibody is administered as a fixed dose of 1500 mg, intravenously, Q3W or wherein the human anti-PD-L1 antibody is administered as a dose of 20 mg/kg, intravenously, Q3W~~.

1~~8~~4. The ~~method~~ use of claim 1~~3~~7, wherein the platinum-based therapeutic agent comprises cisplatin and/or carboplatin.

1~~9~~5. The use~~method~~ of claim 1~~3~~7, wherein the human anti-PD-L1 antibody or antigen binding fragment thereof comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

~~20. The method of claim 17, wherein the human anti-PD-L1 antibody comprises: a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.~~

16~~21~~. The use~~method~~ of claim 1~~3~~7, wherein the human anti-PD-L1 antibody is durvalumab~~, avelumab, or atezolizumab~~.

17. The use of claim 13, wherein the human anti-PD-L1 antibody is to be administered as a fixed dose of 1500 mg, intravenously, Q3W or as a dose of 20 mg/kg, intravenously, Q3W.

~~22~~18. The ~~method~~ use of claim 17, wherein the ~~method~~ use comprises 4 cycles of administration of the human anti-PD-L1 antibody.

~~23~~19. The ~~method~~ use of claim 17 or 18~~22~~, wherein EP is to be administered as a dose comprising 80-100 mg/m$^2$ etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m$^2$, intravenously, per dose of human anti-PD-L1 antibody.

20~~4~~. The ~~method~~ use of any one of claims 17~~, 22, or 23~~-19, wherein ~~further comprising administration of~~ 1500 mg human anti-PD-L1 antibody is to be administered, intravenously, Q4W after completion of 4 cycles of Q3W.

~~25~~21. The use of any one of claims 17-19, wherein a human anti-CTLA-4 antibody is to be administered, intravenously, Q3W, wherein the human anti-CTLA-4 antibody is tremelimumab~~method of any one of claims 17, 22, or 23 further comprising administration of a human anti-CTLA-4 antibody, intravenously, Q3W~~.

~~26. The method of claim 25, wherein the human anti-CTLA-4 antibody is tremelimumab.~~

22~~7~~. The use of claim 21, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kg~~method of claim 26, wherein tremelimumab is administered as a fixed dose of 75 mg~~.

~~28. The method of claim 26, wherein tremelimumab is administered as a dose of 1 mg/kg.~~

23~~9~~. The use according to any one of claims 13-22, wherein prophylactic cranial irradiation is to be administered~~method according to any one of claims 17-28, further comprising administration of prophylactic cranial irradiation~~ to the patient.

~~30. The method according to any one of claims 17-29, further comprising treating the patient with a human anti-PD-1 antibody.~~

2431. The use according to any one of claims 13-23, wherein the medicament includes a human anti-PD-1 antibody~~method of claim 30~~, wherein the human anti-PD-1 antibody comprises pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®).

~~32. The method of claim 17, wherein OS is extended by at least about three months versus treatment with EP alone.~~

3325. Use of a) a human anti-PD-L1 antibody or an antigen binding fragment thereof, b) etoposide and a platinum-based therapeutic agent (EP) in the manufacture of a medicament for ~~A method of~~ improving overall response rate (ORR) in a patient with extensive-stage small cell lung cancer (ES-SCLC), wherein the human anti-PD-L1 antibody or antigen binding fragment thereof comprising:

a VH CDR1 having the amino acid sequence of SEQ ID NO: 3,

a VH CDR2 having the amino acid sequence of SEQ ID NO: 4,

a VH CDR3 having the amino acid sequence of SEQ ID NO: 5,

a VL CDR1 having the amino acid sequence of SEQ ID NO: 6,

a VL CDR2 having the amino acid sequence of SEQ ID NO: 7, and

a VL CDR3 having the amino acid sequence of SEQ ID NO: 8; and

wherein ORR is increased by at least 10% versus treatment with EP alone~~comprising treating the patient with~~

~~a) a human anti-PD-L1 antibody and~~

~~b) etoposide and a platinum-based therapeutic agent (EP),~~

~~wherein the human anti-PD-L1 antibody is administered as a fixed dose of 1500 mg, intravenously, Q3W or wherein the human anti-PD-L1 antibody is administered as a dose of 20 mg/kg, intravenously, Q3W~~.

3426. The ~~method~~ use of claim 2533, wherein the platinum-based therapeutic agent comprises cisplatin and/or carboplatin.

2735. The ~~method~~ use of claim 2533, wherein the human anti-PD-L1 antibody comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.

~~36. The method of claim 33, wherein the human anti-PD-L1 antibody comprises: a VH CDR1 having the amino acid sequence of SEQ ID NO: 3; and a VH CDR2 having the amino acid sequence of SEQ ID NO: 4; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 5; and a VL CDR1 having the amino acid sequence of SEQ ID NO: 6; and a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 8.~~

2837. The ~~method~~ use of claim 2533, wherein the human anti-PD-L1 antibody is durvalumab~~, avelumab, or atezolizumab~~.

29. The use of claim 25, wherein the human anti-PD-L1 antibody is to be administered as a fixed dose of 1500 mg, intravenously, Q3W or as a dose of 20 mg/kg, intravenously, Q3W.

308. The ~~method~~ use of claim 2933, wherein the ~~method~~ use comprises 4 cycles of administration of the human anti-PD-L1 antibody.

319. The use~~method~~ of claim 2933 or 308, wherein EP is to be administered as a dose comprising 80-100 mg/m$^2$ etoposide and carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m$^2$, intravenously, per dose of human anti-PD-L1 antibody.

3240. The ~~method~~ use of any one of claims 29-31, wherein ~~33, 38, or 39 further comprising administration of~~ 1500 mg human anti-PD-L1 antibody is to be administered, intravenously, Q4W after completion of 4 cycles of treatment.

3341. The use of any one of claims 29-31, wherein a human anti-CTLA-4 antibody is to be administered, intravenously, Q3W wherein the human anti-CTLA-4 antibody is

tremelimumabmethod of any one of claims 33, 38, or 39 further comprising administration of a human anti-CTLA-4 antibody, intravenously, Q3W.

42. The method of claim 41, wherein the human anti-CTLA-4 antibody is tremelimumab.

3443. The use of claim 33, wherein tremelimumab is to be administered as a fixed dose of 75 mg or as a dose of 1 mg/kgmethod of claim 42, wherein tremelimumab is administered as a fixed dose of 75 mg.

44. The method of claim 42, wherein tremelimumab is administered as a dose of 1 mg/kg.

4535. The use according to any one of claims 25-34, wherein prophylactic cranial irradiation is to be administered method according to any one of claims 33-44, further comprising administration of prophylactic cranial irradiation to the patient.

46. The method according to any one of claims 33-45, further comprising treating the patient with a human anti-PD-1 antibody.

4736. The use according to any one of claims 25-35, wherein the medicament includes a human anti-PD-1 antibodymethod of claim 46, wherein the human anti-PD-1 antibody comprises pembrolizumab (KEYTRUDA®) or nivolumab (OPDIVO®).

48. The method of claim 33, wherein ORR is increased by at least 10% versus treatment with EP alone.

49. A method of treating ES-SCLC in a patient in need thereof, comprising administering to the patient durvalumab and EP, wherein the durvalumab and EP are administered as a first-line treatment, and, optionally, administering to the patient tremelimumab, wherein the durvalumab is administered as a fixed dose of 1500 mg, intravenously, Q3W or wherein the durvalumab is administered as a dose of 20 mg/kg, intravenously, Q3W.